Tags

Type your tag names separated by a space and hit enter

Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
Clin Microbiol Infect. 2021 Jul; 27(7):958-967.CM

Abstract

BACKGROUND

We lack the rationale on which to base the development of a yellow fever (YF) vaccination schedule for people living with human immunodeficiency virus (PLWHIV).

OBJECTIVES

To report on the current evidence regarding the seroconversion rate and the duration of humoral protection after YF vaccine, as well as the impact of revaccination in PLWHIV.

DATA SOURCES

MEDLINE, Google Scholar, LILACS and Cochrane CENTRAL were searched.

METHODS

We selected studies on PLWHIV of all ages (including perinatally HIV-infected patients) and all settings (YF endemic and non-endemic zones). Intervention investigated was vaccination against YF, at least once after the HIV diagnosis. The research questions were the seroconversion rate, duration of humoral immunity after YF vaccine and impact of revaccination in PLWHIV. Selected studies were assessed for quality using the Newcastle-Ottawa scale.

RESULTS

Ten, six and six studies were selected for the systematic review of each question, respectively. Only one study addressed the first question in perinatally HIV-infected children. The quality of the studies was assessed as Poor (n = 16), Fair (n = 2) or Good (n = 4). A meta-analysis demonstrated that 97.6% (95% CI 91.6%-100%) of the included population seroconverted. Between 1 and 10 years after YF vaccine, reported persistence of neutralizing antibodies was 72% (95% CI 53.6%-91%), and it was 62% (95% CI 45.4%-78.6%) more than 10 years after YF vaccine. No conclusions could be drawn on impact of revaccination because of the small number of patients.

CONCLUSIONS

The current evidence regarding seroconversion rate, duration of humoral protection after YF vaccine and impact of revaccination in PLWHIV is limited by the low number and quality of studies. Based on the presently available data, it is difficult to rationally develop yellow fever vaccination guidelines for PLWHIV.

Authors+Show Affiliations

Infectious Diseases Department, Centre Hospitalier Universitaire Saint-Pierre-Université Libre de Bruxelles, Brussels, Belgium. Electronic address: charlotte.martin@stpierre-bru.be.Robert Koch Institute, Highly Pathogenic Viruses (ZBS 1), Centre for Biological Threats and Special Pathogens, WHO Collaborating Centre for Emerging Infections and Biological Threats, Berlin, Germany.Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.Department of Infectious Tropical Diseases and Microbiology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy.Infectious Diseases Department, Centre Hospitalier Universitaire Saint-Pierre-Université Libre de Bruxelles, Brussels, Belgium.Infectious Diseases Department, Centre Hospitalier Universitaire Saint-Pierre-Université Libre de Bruxelles, Brussels, Belgium.Infectious Diseases Department, Centre Hospitalier Universitaire Saint-Pierre-Université Libre de Bruxelles, Brussels, Belgium; Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium; Environmental Health Research Centre, Public Health School, Université Libre de Bruxelles, Brussels, Belgium.

Pub Type(s)

Journal Article
Systematic Review

Language

eng

PubMed ID

33813107

Citation

Martin, Charlotte, et al. "Immunogenicity and Duration of Protection After Yellow Fever Vaccine in People Living With Human Immunodeficiency Virus: a Systematic Review." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 27, no. 7, 2021, pp. 958-967.
Martin C, Domingo C, Bottieau E, et al. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review. Clin Microbiol Infect. 2021;27(7):958-967.
Martin, C., Domingo, C., Bottieau, E., Buonfrate, D., De Wit, S., Van Laethem, Y., & Dauby, N. (2021). Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 27(7), 958-967. https://doi.org/10.1016/j.cmi.2021.03.004
Martin C, et al. Immunogenicity and Duration of Protection After Yellow Fever Vaccine in People Living With Human Immunodeficiency Virus: a Systematic Review. Clin Microbiol Infect. 2021;27(7):958-967. PubMed PMID: 33813107.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review. AU - Martin,Charlotte, AU - Domingo,Cristina, AU - Bottieau,Emmanuel, AU - Buonfrate,Dora, AU - De Wit,Stéphane, AU - Van Laethem,Yves, AU - Dauby,Nicolas, Y1 - 2021/04/01/ PY - 2020/12/30/received PY - 2021/03/16/revised PY - 2021/03/21/accepted PY - 2021/4/5/pubmed PY - 2021/4/5/medline PY - 2021/4/4/entrez KW - Human immunodeficiency virus KW - Humoral immunity KW - Immunogenicity KW - Neutralizing antibodies KW - Seroconversion KW - Yellow fever revaccination SP - 958 EP - 967 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 27 IS - 7 N2 - BACKGROUND: We lack the rationale on which to base the development of a yellow fever (YF) vaccination schedule for people living with human immunodeficiency virus (PLWHIV). OBJECTIVES: To report on the current evidence regarding the seroconversion rate and the duration of humoral protection after YF vaccine, as well as the impact of revaccination in PLWHIV. DATA SOURCES: MEDLINE, Google Scholar, LILACS and Cochrane CENTRAL were searched. METHODS: We selected studies on PLWHIV of all ages (including perinatally HIV-infected patients) and all settings (YF endemic and non-endemic zones). Intervention investigated was vaccination against YF, at least once after the HIV diagnosis. The research questions were the seroconversion rate, duration of humoral immunity after YF vaccine and impact of revaccination in PLWHIV. Selected studies were assessed for quality using the Newcastle-Ottawa scale. RESULTS: Ten, six and six studies were selected for the systematic review of each question, respectively. Only one study addressed the first question in perinatally HIV-infected children. The quality of the studies was assessed as Poor (n = 16), Fair (n = 2) or Good (n = 4). A meta-analysis demonstrated that 97.6% (95% CI 91.6%-100%) of the included population seroconverted. Between 1 and 10 years after YF vaccine, reported persistence of neutralizing antibodies was 72% (95% CI 53.6%-91%), and it was 62% (95% CI 45.4%-78.6%) more than 10 years after YF vaccine. No conclusions could be drawn on impact of revaccination because of the small number of patients. CONCLUSIONS: The current evidence regarding seroconversion rate, duration of humoral protection after YF vaccine and impact of revaccination in PLWHIV is limited by the low number and quality of studies. Based on the presently available data, it is difficult to rationally develop yellow fever vaccination guidelines for PLWHIV. SN - 1469-0691 UR - https://www.unboundmedicine.com/medline/citation/33813107/Immunogenicity_and_duration_of_protection_after_yellow_fever_vaccine_in_people_living_with_human_immunodeficiency_virus:_a_systematic_review_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(21)00139-7 DB - PRIME DP - Unbound Medicine ER -